Patent ID: 9732151
Date: 2017-08-15
CPC Classifications: C07K,C12Q,G01N

Claim:
1. A method of treating a mammalian subject with asthma or atopic dermatitis with an anti-thymic stromal lymphopoietin (TSLP) antibody comprising: measuring expression of biomarkers in a sample from said subject, wherein the biomarkers comprise Lipocalin 2(LCN2), Peptidoglycan Recognition Protein 1(PGLYRP1) and RNASE3; Regenerating Islet-derived 3 gamma (REG3G), CD44, and RNASE7; RNASE2, Acidic Mammalian Chitinase(AMCASE), and Chitinase Acidic Pseudogene 2(CHIAP2); or PGLYRP1, REG3G, and AMCASE, and, if the biomarker levels in the sample are higher than a control, administering a therapeutically effective amount of an anti-TSLP antibody to the subject.